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Objectives: The aim of the study was to investigate the changes in costs and outcomes after the implementation
of various disease management programs (DMPs), to identify their potential determinants, and to compare the
costs and outcomes of different DMPs.
Methods: We investigated the 1-year changes in costs and effects of 1,322 patients in 16 DMPs for cardiovascular risk
(CVR), chronic obstructive pulmonary disease (COPD), and diabetes mellitus (DMII) in the Netherlands. We also explored
the within-DMP predictors of these changes. Finally, a cost-utility analysis was performed from the healthcare and societal
perspective comparing the most and the least effective DMP within each disease category.
Results: This study showed wide variation in development and implementation costs between DMPs (range:€16;€1,709)
and highlighted the importance of economies of scale. Changes in health care utilization costs were not statistically
significant. DMPs were associated with improvements in integration of CVR care (0.10 PACIC units), physical activity
(+0.34 week-days) and smoking cessation (8% less smokers) in all diseases. Since an increase in physical activity and in
self-efficacy were predictive of an improvement in quality-of-life, DMPs that aim to improve these are more likely to be
effective. When comparing the most with the least effective DMP in a disease category, the vast majority of bootstrap
replications (range:73%;97) pointed to cost savings, except for COPD (21%). QALY gains were small (range:0.003;+0.013)
and surrounded by great uncertainty.
Conclusions: After one year we have found indications of improvements in level of integrated care for CVR patients and
lifestyle indicators for all diseases, but in none of the diseases we have found indications of cost savings due to DMPs.
However, it is likely that it takes more time before the improvements in care lead to reductions in complications and
hospitalizations.
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Chronic diseases pose an increasing threat to population
health, enlarge the burden of care giving, and constrain
the financial viability of health care systems worldwide.
Because these health care systems originate largely from
an era where acute and infectious diseases were more* Correspondence: tsiachristas@bmg.eur.nl
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article, unless otherwise stated.prominent, their design is not optimal for chronic care
[1]. This triggered many new approaches for providing
continuous, integrated, pro-active and patient-centred
care by a multidisciplinary team of care providers in order
to improve health outcomes and reduce costs. There is
evidence that these approaches improve the quality of the
care as measured by process indicators like coordination of
care, communication between caregivers, patient satisfac-
tion, provider adherence to guidelines, and patient adher-
ence to treatment recommendations [2]. However, there is
debate about the impact on health outcomes and efficiencytral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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study designs, outcome metrics and target populations
across studies [3] as well as cultural and political barriers to
evaluation [4].
In the Netherlands, a recently established regulation
introduced a bundled payment system to promote
disease management programs (DMPs) for patients with
diabetes mellitus type two (DMII), chronic obstructive
pulmonary disorder (COPD) or at risk for a cardiovascu-
lar disease (CVD) event [5]. Although, the wide-scale
implementation of DMII-DMPs was smooth and suc-
cessful, the uptake of DMPs for COPD and cardiovascu-
lar risk (CVR) is still troublesome. This is because health
insurers, which contract DMPs from care groups, are yet
to be convinced about the financial attractiveness of
these programs [6]. Illustrative of this scepticism is that
the largest Dutch health insurer does not contract CVR-
DMPs and provides only a yearly add-on payment per
patient with an elevated CVR to cover costs of coordin-
ation, provider training and additional ICT support.
Another large health insurer contracts CVR-DMPs
only for patients diagnosed with a CVD (secondary
prevention) and not for individuals at risk to have CVD
(primary prevention). In addition, the debate embeds the
adequacy of the current single-disease DMPs for patients
with multiple morbidities, which seems to be the norm
rather than the exception [7].
Therefore, the provision of evidence about the vari-
ability in costs and effects of different implemented
DMPs is eminent for the successful implementation of
integrated chronic care in the Netherlands. This study
aims to investigate the changes in costs and outcomes
after the implementation of DMPs, to identify potential
determinants of them, and to compare the costs and
outcomes of different DMPs.
Methods
Design and setting
In a prospective pre-post study, we compared 16 different
DMPs spread across different regions of the Netherlands
[8]: 9 CVR-, 4 COPD-, and 3 DMII-DMPs. Two CVR-
DMPs included patients that were at risk for developing
CVD (primary prevention), two CVR-DMPs patients that
had already been diagnosed with CVD (secondary preven-
tion), and five CVR-DMPs included both patient groups.
The implementation of the DMPs and their participation
in the evaluation study was financially supported by the
Netherlands Organization for Health Research and
Development (ZonMw, project number 300030201).
Outcomes and health care resource utilization were
measured twice, once at the start of the DMP and
once after approximately 12 months, using a patient-
questionnaire. A detailed description of the design and
setting is presented in Lemmens et al. [8].Intervention
To describe the details of each DMP we read program
documents and interviewed DMP managers using a
check-list of possible interventions that may be included
in such programs, grouped by the components of the
chronic care model [9]. Although the services included
in the integrated care package differed between the
DMPs, most programs focused on improving the
collaboration between different disciplines of health care
professionals and redesigning the care-giving process to
patient centred care more proactively. Most of them
provided interventions such as self-management education
and training directed at life-style improvement (physical
reactivation, smoking cessation, diet improvement),
decision support to implement guidelines and protocols,
integration of ICT systems, training for health care
providers, case management, and reallocation of tasks
between care providers [8,10]. A detailed presentation
of the interventions provided by each DMP is provided
by Additional file 1.
Outcomes
We investigated the impact of the DMPs on a broad
range of outcomes including changes in care delivery
process, patient life-style and self-management behav-
iour, and health-related quality of life (HR-QoL) [9].
More specifically, we investigated the impact of DMPs
on: a) the level of chronic care integration using the Pa-
tient Assessment Chronic Illness (PACIC) questionnaire
[11], b) patient life-style measured by self-reported smoking
status (current, former or never smoker) and physical
activity (expressed in the number of days per week that an
individual had more than 30 minutes physical activity), c)
self-efficacy using the respective subscale of the
Self-Management Ability Scale- Shorter (SMAS-S)
[12], and d) the 3-level EQ-5D utility scores which
were based on the Dutch value set and used to estimate
quality adjusted life years (QALYs) [13]. The questionnaire
designed to measure these outcomes also included ques-
tions about socio-demographic patient characteristics and
a checklist of morbidities.
Costs
We estimated five categories of costs, i.e. 1) the develop-
ment costs, 2) the implementation costs, 3) the costs of
health care utilization, 4) the costs borne by patient for
travelling to receive care and 5) the costs of productivity
loss due to absence from paid work. When calculating
costs from a healthcare perspective cost categories 1, 2,
and 3 were included; categories 4 and 5 were added
when adopting the societal perspective.
The development costs included all costs made during
the preparation phase of DMPs e.g. labour costs for
brainstorming sessions, training costs, and ICT support
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curred after the provision of DMP interventions to
patients had started and included the costs for managing
the DMP, the costs of multidisciplinary team meetings,
the costs associated with collecting quality of care indi-
cators for audit and feedback, the costs of materials used
for patient education, and the costs of keeping the ICT
operating. The development and implementation costs
were systematically collected using a template based on
the CostIt instrument of the World Health Organisation
(WHO) [14]. This template was completed during face-
to-face interviews with DMPs managers. During these
interviews managers were also asked about the presence
of additional funding to cover the specific elements of
integrated care. Capital costs were amortized over their
life span and allocated to the DMP based on square me-
ters for the costs of buildings, full-time equivalents for
the costs of ICT and medical technologies (e.g. spirom-
eter). The sum of the capital costs and the operating
costs of a DMP was then divided by the number of
DMP participants. The costs of developing a DMP were
amortized in 5 years assuming this period as the life
span of a DMP since after this period changes in guide-
lines and governmental policies would probably affect
the initial form of a DMP. The development and imple-
mentation costs per patient were consequently calcu-
lated by adding one fifth of the development costs to the
annual implementation costs and dividing it by the
number of DMP participants.
The costs of health care utilization were based on a
questionnaire asking patients about the number of care-
giver contacts (GP, nurse practitioner, nurse, dietician,
physiotherapist, podiatrist, lifestyle coach, medical spe-
cialists in outpatient clinics etc.), hospital admissions
and admission days, and medication use. The recall
period for these questions was 3 months and we asked
for all health care utilization, whether or not it was re-
lated to the disease targeted in the DMP. In addition to
these costs, the travel costs of patients were calculated,
using their self-reported distance to a health care pro-
vider. Finally, the costs of productivity loss due to illness
were calculated, using the friction cost approach [15],
based on questions about absence from paid employment
due to illness. Standard unit costs as reported by [16] were
applied. All costs were inflated to 2012 and reported on
an annual basis per patient (see Additional file 2).
Statistical analysis to estimate changes within DMPs
We started with paired Wilcoxon tests and McNemar
chi-square tests to investigate whether the differences in
costs and effects between the baseline and follow-up
measurements were statistically significant. In addition,
a multi-level analysis was performed to explore the
determinants of change in costs and EQ-5D utilities ofpatients clustered in DMPs. Generalized linear mixed
models were used to accommodate the skewness in the
health care utilization cost and EQ-5D data as well as to
include predictor variables on patient and DMP level.
Predictor variables on patient level included: the EQ-5D
or costs at baseline (depending which of the two was the
outcome variable), age, physical activity at baseline and
its change, the PACIC score at baseline and its change,
the SMAS-self-efficacy score at baseline and its change,
smoking cessation during the follow-up period, and pres-
ence of multi-morbidity. Gender, socio-economic status,
and marital status were not included in the final model
after performing likelihood ratio tests. Predictor variables
on the DMP level included the DMP target population and
the existence of additional payments to cover overhead and
management expenses provided on top of the usual
payment per patient.
To explore the variance in the change in outcomes
and costs between DMPs that targeted patients at risk
for a first (primary prevention), or subsequent CVD
event (secondary prevention), or both types of CVR
prevention, we also estimated separate models for
these sub-groups.
Statistical analysis to estimate differences between DMPs
In each disease category, we identified the DMP that
was most effective and least effective in improving the
patients’ generic health-related quality of life as mea-
sured in QALYs. In this manner we identified 5 pairs of
DMPs (i.e. for primary CVR prevention, secondary CVR
prevention, both types of CVR prevention, COPD, and
DMII). For each of the 5 pairs, we calculated the cost-
utility of the most effective versus the least effective
DMP in terms of incremental costs per QALY gained.
These calculations were performed from two perspec-
tives, i.e. the health care perspective (cost category one
to three) and the societal perspective (all five categories
of costs).
We used inverse probability weighting to balance the
two comparators in each pair with respect to age, gender,
education, presence of multi-morbidity, marital status,
and EQ-5D at baseline. Inverse probability weighting was
chosen because it is the preferred propensity score match-
ing technique for small samples [17]. We performed boot-
strapping to generate 5,000 samples from the original
sample. For each bootstrapped sample we estimated a gen-
eralized linear model for each outcome variable (i.e. QALYs
or costs) using the inverse probability weights to get the co-
efficients adjusted for the propensity score of each observa-
tion as well as age, gender, education level, multi-morbidity,
and marital status. We used inverse Gaussian distribution
and power minus two link for the QALY estimation and
gamma distribution and log link for the costs estimation. In
this manner, 5,000 predicted incremental costs and 5,000
Table 1 Sample size per disease and measurement moment
Disease DMPs Baseline Follow-up Baseline & follow-up
Total 16 2,438 1,974 1,322
CVR 9 1,342 1,125 725
COPD 4 689 596 395
DMII 3 407 253 202
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5,000 ICERs was calculated as the mean of the predicted
incremental costs divided by the mean of the incremental
QALYs. These predicted ICERs were then plotted on a cost-
effectiveness (CE) plane to show the uncertainty in the ICER.
Sensitivity analysis
The CUA was also performed excluding the development
and implementation costs in order to investigate how
sensitive the estimated ICERs are to these costs.
Results
Sample
As Table 1 shows, there were 2,438 respondents at the
baseline measurement and 1,974 respondents at the
follow-up measurement. One thousand three hundred
twenty two individuals responded to both measurements
(i.e. had complete data).
The sample characteristics by disease are presented in
Table 2. The mean age of the total sample was 65.1 years
and consisted of 47% females, 38% low educated, 38%
employed, and 30% singles. The mean multi-morbidity
among the respondents measured by the Charlson co-
morbidity index [18] was 1.83. The COPD sample included
proportionally more low-educated, unemployed, and single
patients than the other two samples. COPD patients were
also older and had higher Charlson co-morbidity scores.
Table 3 presents the baseline values of the outcome mea-
sures and their change after one year. The perceived level




Age 64.1 (9.7) 66.5 (1
[59.6;67.8] [65.4;6
% Females 48 48
Charlson comorbidity index 1.48 (1.10) 2.26 (1
% Low education 35 48
% Employment 43 30
% Single 26 36
The table presents the mean (sd) unless otherwise indicated; in [] is given the rang
disease area; low education was defined as no or only primary education; The p-va
**Statistically different at p < 0.01 between the diseases.among patients in DMII-DMPs (3.29) and the lowest in
CVR-DMPs (2.80). Individuals in CVR-DMPs were the
most physically active at baseline (5.00 days per week) while
diabetic patients were the least physically active (4.74 days).
In addition, the percentage of smokers was the highest in
the COPD sample (39%) and the lowest in the CVR sample
(21%). Patients in DMII-DMPs had scored the highest in
self-efficacy (4.56) and patients in COPD-DMPs the lowest
(4.33). The mean EQ-5D utility score at baseline was 0.83
in the CVR sample and 0.84 in the DMII sample while for
the COPD sample it was lower (0.79).
Changes in outcomes
Changes in PACIC scores were significantly positive (0.10)
in the CVR sample (range across the 9 CVR DMPs from
+0.02 to +0.26) and significantly negative (−0.23) in the
DMII sample (range across the 3 DMII-DMPs from −0.27
to −0.18). In the CVR and COPD samples the change in
the number of days per week with more than 30 minutes of
physical activity was positive and statistically significant
(0.33 and 0.37 respectively). The range in physical active
days across the CVR and COPD-DMPs was quite large as
Table 3 shows. The percentage of smokers decreased sub-
stantially in all samples (ranging across all 16 DMPs from
−13.7 percentage points to −2.5 percentage points) as well
as the self-efficacy (ranging from −0.48 percentage points
to 0.15 percentage points) and the HR-QoL (ranging from
−0.06 percentage points to +0.03 percentage points).
Changes in costs
The development and first year’s implementation costs per
patient of the 16 DMPs are presented in Table 4. As this
table shows, there is large variation in the implementation
costs per patient between and within the three diseases
ranging from €16 to €1,709. This is due to the variation in
the total development and implementation costs and the
number of participants per DMP. The largest share of these
costs is for costs related to the time that personnelDMII Total sample
(sd) Mean (sd) Mean (sd)
range] [DMP range] [DMP range]
0.0) 66.2 (9.7) 65.1** (9.9)
9.3] [64.2;67.1] [59.6;69.3]
43 47




e between DMPs i.e. lowest and highest values across DMPs in the same
lues show whether the values are statistically different between the diseases
Table 3 Outcomes by disease at baseline and differences with the outcomes in the follow-up




























(1; 5 highest = best)
2.80 (0.84) 0.10** (0.80) +0.02; +0.26 2.92 (0.89) −0.03 (0.75) −0.05; +0.06 3.29 (0.85) −0.23* * (0.72) −0.27; − 0.18 0.01 (0.78) −0.27; +0.26
Physically active days
per week
5.00 (2.07) 0.33** (2.15) −0.23; +0.82 4.82 (2.13) 0.37** (2.20) −0.11; +1.36 4.74 (1.94) 0.29 (2.01) +0.05; +0.89 0.34** (2.14) −0.23; +1.36
% smokers 21 −6 pp** −2.5 pp; −10.7 pp 39 −11 pp** −7.3 pp;-13.7 pp 22 −9 pp** −8 pp; −13.6 pp −8 pp** −13.7 pp; −2.5 pp
Self-efficacy
(1; 6 highest = best)
4.45 (0.87) −0.28** (0.75) −0.33; − 0.15 4.33 (0.88) −0.34** (0.73) −0.48; −0.27 4.56 (0.85) −0.29** (0.77) −0.42; −0.22 −0.30** (0.75) −0.48; −0.15
EQ-5D
(−0.33; 1 highest = best)
0.83 (0.18) −0.01* (0.16) −0.06; +0.03 0.79 (0.20) −0.04** (0.19) −0.04; − 0.03 0.84 (0.16) −0.03* (0.14) −0.04; −0.02 −0.02** (0.17) −0.06; +0.03



















Table 4 Development and implementation costs by DMP















CVR-DMP 1 300 52,136 174 35 16,426 55 90
CVR-DMP 2 207 54,417 263 53 68,415 331 381
CVR-DMP 3 700 98,754 141 28 153,215 219 234
CVR-DMP 4 300 274,783 916 183 171,026 570 605
CVR-DMP 5 550 26,807 49 10 67,604 123 142
CVR-DMP 6 450 27,923 62 12 149,990 333 356
CVR-DMP 7 125 13,324 107 21 37,968 304 387
CVR-DMP 8 250 195,007 780 156 168,385 674 715
CVR-DMP 9 1,000 26,678 27 5 81,258 81 92
COPD-DMP 1 2,508 154,504 62 12 214,239 85 90
COPD-DMP 2 1,600 93,909 59 12 49,751 31 38
COPD-DMP 3 133 49,639 373 75 55,191 415 493
COPD-DMP 4 2,400 44,586 19 4 32,599 14 18
DMII-DMP 1 2,400 5,891 2 0 28,061 12 16
DMII-DMP 2 233 162,889 699 140 387,879 1,655 1,709
DMII-DMP 3 300 50,304 168 34 61,338 204 239
*We used 5 years as amortization period; #These costs are not per patient.
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to educational courses for caregivers and information
brochures for patients were low in almost all cases (except
in DMII-DMP1). In some DMPs “other” costs such as ICT,
energy, and accommodation costs were relatively high (e.g.
66% in DMII-DMP 2).
At baseline, patients in COPD-DMPs had the highest
mean yearly hospital costs (€1,967), medication costs
(€857), total health care costs (€4,368) and total costs
(€5,320) while patients in CVR-DMPs had the highest
mean yearly productivity loss (€1,648) (see Table 5). Pa-
tients in DMII-DMPs had the highest primary care costs
(€941). However, almost all differences between baseline
and follow-up were statistically insignificant and the stand-
ard deviations of the estimated means were large. Only the
outpatient costs of patients with diabetes increased by
€115. As Table 5 shows, the changes across DMPs within
the same disease and between diseases varied largely. The
cost change within each disease category ranged from
negative to positive across DMPs except for the outpatient
costs and inpatient costs of patients with diabetes.
In primary and mixed prevention CVR-DMPs, the
PACIC was increased by 0.18 and 0.10 and the number of
days with at least 30 minutes of physical activity in a week
increased by 0.43 and 0.37, respectively (Table 6). The
decrease in the percentage of smokers ranged from 3%
(primary prevention) to 8% (secondary prevention). As
Table 6 shows, self-efficacy was decreased in all three typesof CVR prevention by about 0.28 while the EQ-5D
decreased in the mixed CVR prevention DMPs by 0.02.
Table 6 presents the yearly costs and outcomes of
patients enrolled in CVR-DMPs that target different popu-
lations (i.e. primary prevention, secondary prevention, or
both types of prevention). After 12 months, the hospital
costs of patients included in DMPs targeting both types of
CVR prevention increased by €819 within a year. Further,
patients in DMPs for secondary prevention and for both
types of prevention had €48 and €5 lower travelling costs,
respectively. The travelling costs at baseline in these two
types of DMPs were also higher compared to the primary
prevention DMPs.
Determinants of changes in HR-QoL and costs within DMPs
The results from the generalized linear mixed models are
presented in Table 7. Model one shows that a greater
improvement in EQ-5D utility is significantly predicted by
a lower baseline EQ-5D score, a higher baseline physical
activity level, a greater increase in physical activity, and a
greater increase in self-efficacy. One additional day with
more than 30 minutes of physical activity leads to a 3%
higher EQ-5D utility and 1 unit of increase in self-efficacy
score leads to a 4% higher EQ-5D utility. In contrast,
patients with COPD had 7% less improvement in EQ-5D
and patients with multi-morbidity 5% less.
The best predictors of change in health care utilization
costs were health care utilization costs at baseline and the
Table 5 Costs at baseline and differences with the follow-up measurement



























Primary care 610 (857) 34 (1,069) −510; +314 916 (1388) 49 (1,601) −5; +155 941 (947) −84 (1,226) −236; +88 21 (1,273) −510; +314
Outpatient hospital care 365 (778) 30 (954) −443; +259 654 (2,488) −119 (2,524) −272; +22 338 (604) 115* (809) +86; +169 −2* (1,583) −443; +259
Inpatient hospital care$ 587 (3,526) 624 (9,452) −551; +2,148 1,967 (13,256) 320 (18,563) −396; +1,162 701 (3,714) −454 (4,065) −1,211; − 220 368 (12,426) −1,211; +2,148
Medication 370 (362) 3 (261) −45; +41 857 (601) 3 (417) −2; +6 518 (482) 1 (318) −44; +34 3 (323) −45; +41
Total healthcare
utilization costs
1,911 (4,102) 691 (9,812) −1,107; +2,626 4,368 (14,256) 238 (19,080) −672; +1,055 2,504 (4,015) −446 (4,444) −93; −1,066 382 (12,826) −1,107; +2,626
Travelling 74 (215) −2 (344) −113; +90 226 (1,190) −109 (1,145) −328; +47 174 (378) −22 (441) −23; −19 −37** (699) −328; +90
Productivity 1,648 (8,080) −495 (7,349) −1,988; +1,075 658 (4,724) 341 (6,603) 0; +459 216 (1,410) 188 (2,656) −210; +454 −102 (6,571) −1,988; +1,075
Total costs 3,302 (9,006) 468 (13,559) −1,893; +4,269 5,320 (15,390) 85 (20,354) −1,232; +375 3,489 (7,605) −517 (9,662) −1,591; − 167 203 (15,448) −1,893; +4,269
$inpatient hospital care costs include also emergency care costs; *(p < 0.05); **(p < 0.01); the differences are calculated subtracting the costs at baseline from the costs at follow-up; primary care costs included contacts



















Table 7 Determinants of changes in HR-QoL and health
care utilization costs
Model 1 Model 2
Change in
EQ-5D
Change in health care
utilization costs
e(b) p e(b) p
Intercept 1.04 0.744 104192.98 <0.001
EQ-5D/ 0.60 <0.001
Costs (in 000’s) baseline 0.95 <0.001
Age 1.00 0.408 1.00 0.130
Physical activity (1–7 highest) 1.02 0.023 1.00 0.777
Change in physical activity 1.03 0.001 1.00 0.639
PACIC (1–5 highest) 0.99 0.474 1.02 0.247
Change in PACIC 1.00 0.830 1.00 0.843
Self-efficacy (1–6 highest) 1.00 0.956 0.98 0.107
Change self-efficacy 1.04 0.032 1.01 0.730
Quit smoking (1 = yes) 1.04 0.119 1.07 0.104
Multi-morbidity (1 = yes) 0.95 0.019 1.06 <0.001
COPD* (1 = yes) 0.93 <0.001 1.01 0.541
DMII* (1 = yes) 0.99 0.576 1.02 0.460
Additional payment (1 = yes) 0.99 0.468 0.99 0.491
N 820 843
R2 patient level 0.36 0.73
R2 DMP level 0.56 0.78
*the reference category is CVR-DMP; Note: the predictor variables COPD-DMP,
DMII-DMP, and Additional payment are on the DMP level. All other variables
are on the patient level.
Table 6 Costs and outcomes by type of CVR prevention
Primary prevention Secondary prevention Mixed
Baseline Change Baseline Change Baseline Change
PACIC (1–5 highest) 2.64 (0.77) 0.18* (0.76) 2.52 (0.79) 0.09 (0.75) 2.92 (0.84) 0.10* (0.82)
Physically active days per week 5.25 (1.91) 0.43* (1.94) 5.15 (2.10) 0.12 (2.11) 4.91 (2.10) 0.37** (2.20)
% smokers 13 −3* 30 −8** 20 −6**
Self-efficacy (1–6 highest) 4.44 (0.85) −0.29** (0.75) 4.32 (0.92) −0.30** (0.77) 4.48 (0.86) −0.27** (0.74)
EQ-5D 0.85 (0.17) −0.01 (0.15) 0.77 (0.22) 0.01 (0.19) 0.84 (0.17) −0.02* (0.15)
Primary care costs 555 (827) −16 (701) 810 (1,153) −149 (1,191) 565 (751) 97 (1,092)
Outpatient hospital care 326 (662) −104 (643) 725 (1,342) −34 (1,728) 269 (492) 76* (657)
Inpatient hospital care$ 471 (3,009) −334 (3,120) 1,064 (5,012) 932 (9,807) 476 (3,085) 742 (10,225)
Medication costs 269 (275) 0 (248) 493 (423) 1 (289) 356 (351) 4 (255)
Total healthcare utilization costs 1,600 (3,665) −447 (3,663) 3052 (5,787) 754 (10,204) 1,653 (3,525) 918 (10,574)
Travelling costs 63 (145) 73 (571) 89 (221) −48* (185) 72 (226) −5* (312)
Productivity costs 3,542 (11,480) −1,685 (10,076) 1,119 (6,401) −86 (6,964) 1,405 (7,646) −368 (6,743)
Total costs 3,633 (10,091) −317 (11,593) 4,421 (10,657) 159 (13,876) 2,911 (8,201) 725 (13,874)
The table presents the mean (SD) and the mean difference (SD) between baseline and follow-up measurements; $inpatient hospital care costs include also
emergency care costs; *(p < 0.05); **(p < 0.01); the differences are calculated subtracting the costs at baseline from the costs at follow-up; primary care costs
included contacts with GP, nurse practitioner, nurse, dietician, physiotherapist, podiatrist, lifestyle coach, etc.
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higher at baseline, the increase was 5% less. In case of
multi-morbidity, the cost increase was 6% higher. The
variance in the dependent variables explained by models 1
and 2 at the DMP and the patient level was relatively high.
Comparing costs and effects between DMPs
The results from the cost-utility analysis taking the health
care and societal perspective are presented in Table 8. This
table shows that the most effective DMP for CVR primary
prevention, combined primary and secondary CVR preven-
tion, and DMII led to statistically significant cost savings
when compared to the least effective DMP in the same dis-
ease category (i.e. more than 95% of bootstrap replications
in the southern quadrants). It also shows there is large vari-
ation in incremental costs (ranging from €-721 to €1,716)
and incremental QALYs (ranging from 0.003 to 0.013)
between the best and the worst DMP within a disease cat-
egory. Due to the very small incremental QALYs the ICERs
are very large. The 5000 bootstrapped ICERs plotted on the
CE plane showed that there is large uncertainty around the
estimated mean ICER. Considering the CVR- primary pre-
vention sample, 97% of the 5,000 simulated ICERs were in
the southern half of the CE plane indicating lower incre-
mental costs while the reverse was observed for the COPD
sample (79% of the 5,000 bootstrapped ICERS were on the
Northern CE plane).
From the societal perspective, the cost-utility results are
similar to the results from the health care perspective
except that for the secondary CVR prevention samples the
uncertainty about the incremental costs became even
larger.
Table 8 Results from the cost-utility analysis






Mean ICER % of 5000 simulated ICERs per quadrant in
the CE plane
NW NE SW SE
Health care perspective
CVR-primary# 7 VS 4 −534 0.003 −178,539 1 3 41 56
(297) (0.021)
CVR-secondary$ 1 VS 3 −671 0.012 −56,809 6 21 15 58
(976) (0.015)
CVR-both 2 VS 8 −721 0.005 −148,480 2 2 35 61
(416) (0.016)
COPD 1 VS 4 1,716 0.009 185,747 33 46 11 10
(2,000) (0.053)
DMII 1 VS 3 −677 0.013 −50,234 1 3 14 82
(398) (0.013)
Societal perspective
CVR-primary# 7 VS 4 −1,131 0.003 −377,991 5 12 37 46
(1,334) (0.021)
CVR-secondary$ 1 VS 3 −153 0.012 −12,929 10 36 11 43
(1,225) (0.015)
CVR-both 2 VS 8 −604 0.005 −124,457 6 8 31 55
(554) (0.016)
COPD 1 VS 4 2,054 0.009 −222,314 34 47 11 9
(2,371) (0.053)
DMII 1 VS 3 −1,735 0.013 −128,790 1 2 14 83
(1,084) (0.013)
*most effective is defined based on the highest incremental QALY and the reverse; #primary prevention for CVD; $secondary prevention for CVD; ICER:
incremental cost-effectiveness ratio; CE: cost-effective(ness); best is defined as most effective based on QALYs and worse as the least effective based on
the same measurement; the numbers correspond to the DMP numbers in Table 4.
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Table 9 shows the results from the CUA performed exclud-
ing the development and implementation costs. The most
remarkable change in comparison to the main CUA is that
20% (instead of 4%) of the 5,000 bootstrapped ICERs
regarding both CVR prevention DMPs were located on the
North quadrant of the CE plane. This change is a result
from the higher development and implementation costs of
the least effective DMP.
Discussion
In this study we have investigated the short-term changes
in costs and effects after the implementation of 16 DMPs
for three different chronic diseases, namely CVR, COPD,
and DMII. We have also explored the within DMP predic-
tors of these changes. Finally, a CUA was performed from
the health care and societal perspective comparing each
DMP to usual care and comparing the most effective and
least effective DMP within five disease categories (i.e. CVR-
primary prevention, CVR-secondary prevention, CVR-both
types of prevention, COPD, DMII).Our results show a significant improvement in the level
of chronic care integration as measured by the PACIC, in
the CVR population (0.10). It improved especially in the
DMPs that were directed at primary prevention (0.18) or
the combination of primary and secondary prevention
(0.10) of cardiovascular diseases. This is promising because
patients in these programs had the lowest PACIC scores of
the three patient groups. For patients who already had a
cardiovascular disease it is probably harder to achieve im-
provements in integrating care because more (para-) med-
ical disciplines and healthcare sectors become involved. An
unexpected result was that the PACIC decreased by 0.23 in
the DMII-DMPs. This may be due to difficulties to main-
tain their high starting level of integrated care, which in
turn may be caused by the attention that was paid to
quality improvements in diabetes care for the last decade. It
would be interesting to examine whether our findings
would have been similar if another instrument, for ex-
ample the Assessment of Chronic Illness Care (ACIC),
would have been used to measure the level of chronic care
integration. However, we did not include the ACIC in our








Mean ICER % of 5000 simulated ICERs per quadrant
in the CE plane
NW NE SW SE
CVR-primary# 7 VS 4 −407 0.003 −136,077 3 7 39 51
(330) (0.021)
CVR-secondary$ 1 VS 3 −863 0.012 −73,013 4 14 17 65
(961) (0.015)
CVR-both 2 VS 8 −326 0.005 −67,145 10 10 28 52
(388) (0.016)
COPD 1 VS 4 1,574 0.009 170,390 32 45 12 11
(1,985) (0.053)
DMII 1 VS 3 −430 0.013 −31,942 3 11 12 74
(402) (0.013)
*most effective is defined based on the highest incremental QALY and the reverse; #primary prevention for CVD; $secondary prevention for CVD; ICER: incremental
cost-effectiveness ratio; CE: cost-effective(ness); best is defined as most effective based on QALYs and worse as the least effective based on the same measurement;
the numbers correspond to the DMP numbers in Table 4.
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focuses on intermediate and final outcomes in patients,
not in professionals. The second is that although the two
instruments are complementary [19], they both measure
the level of integrated care and thus, they correlate [20].
Another interesting finding is that DMPs seem to
improve the life-style of patients, in all three disease
categories. Patients reported a higher level of physical
activity, especially those in DMPs for COPD and CVR
management. In addition, the percentage of smokers
decreased by more than 5 percentage-point in all disease
categories; the decrease was 11 percentage-point in
COPD. This reduction is considerably higher as the
cessation rate achieved by a physician-advice to stop
smoking [21] or the impact of the recent ban on smok-
ing in bars and restaurants [22].
Furthermore, our within-DMP analysis showed a re-
duction in self-efficacy and generic HR-QoL after the
implementation of the DMPs. The slight deterioration
(about 0.03 EQ-5D units) in HR-QoL may be explained
as a time effect rather than a treatment effect because
the HR-QoL of chronic care patients generally tends to
decrease over time [23]. Similarly, the decrease in self-
efficacy may also be related to the decrease of HR-QoL
because deterioration in HR-QoL may worsen self-efficacy
[24,25]. Another explanation may be that HR-QoL and
self-efficacy are both perceived values that are influenced
by the information and knowledge a patient has. DMP
interventions included educating patients about their
disease, learning them to recognize the early signals of
disease-worsening, learning them coping skills and
stimulating them to improve their lifestyle. As a result,
patients may have become more aware of their impaired
health status and their reference point may have shifted.Our study collected the costs of development and
implementation of the DMPs in detail and showed that
they can be an important driver of total costs. This is in
line with the findings of the few previous studies that
have incorporated them in their analysis [3,26,27]. The
development and implementation costs per patient were
largely driven by the personnel costs. Moreover, the 16
DMPs included in our sample were pioneers in experi-
menting with DMPs. Therefore, the number of enrolled
patients was perhaps not as high in the first year of
implementation as the capacity would allow. In the long
(er) term, we expect that more patients will be enrolled
in the DMPs and caregivers will gain experience in
managing and maintaining a DMP. That may lower the
implementation costs per patient. Therefore, we would
expect more favourable ICERs for the DMPs in the lon-
ger term. Within the one-year time frame of our study
there are as yet few signals of important changes in the
costs of healthcare utilization and productivity loss. But
the heterogeneity in DMPs is large with all 3 DMII-
DMPs showing a numerical reduction of hospital costs
and total health care costs.
The regression analysis indicated that an increase in
physical activity was predictive of an increase in HR-
QoL. Given the observed increase in physical activity in
almost all disease categories, we may expect DMPs to
improve HR-QoL in the longer term. We also found that
an improvement in self-efficacy was predictive of an
improvement in HR-QoL. This creates an opportunity for
DMPs to develop and implement strategies to improve the
self-efficacy of the patients. Furthermore, patients with
multiple morbidities seem to benefit less than patients with
one disease. This may imply that the current disease-
specific DMPs do not address the needs that patients with
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this population. The need for patient-tailored care to ad-
dress the complex needs of patients with multi-morbidity is
extensively addressed in the literature [28,29]. A horizontal
integration of DMPs to simultaneously target CVR, COPD,
and DMII might be appealing for several reasons. The first
one is of course the desire to improve the care for these pa-
tients. The second reason is that some components of the
DMPs are largely similar, irrespective of the disease. For ex-
ample, smoking cessation support and physical reactivation
can be organized similarly, and adjusted to the specific
needs of an individual patient. This avoids inefficiencies
and double payments. Another reason is that the number
of participants in such a multi-disease DMPs will increase,
which will lower the implementation and overhead costs
per participant.
We also performed a CUA comparing DMPs within a
disease area, which is interesting for decision makers once
they have decided to implement a DMP. Then the variability
in costs and health outcomes is likely to drive the choice of
program. When adopting the health care perspective the
CUA showed that the majority of the bootstrapped ICERs in
all types of CVR prevention and DMII comparison pairs
were located on the South-East quadrant of the CE plane.
This indicates that the most effective DMPs had lower costs
and positive QALY gains compared to the least effective
DMPs in these three disease groups. This finding remained
also when the societal perspective was adopted. However, the
results concerning the primary CVR prevention and COPD
were more difficult to interpret because of the uncertainty
about the QALYgains (health care and societal perspective).
As our results showed, the cost-effectiveness of DMPs
varies considerably, most likely depending on the com-
ponents of the program, the target population, the suc-
cess of the implementation and the costs of managing
and operating the program. These are all factors that
contractors of DMPs should consider in the negotiation
phase. We are planning future analysis aiming to identify
the factors that drive the cost-effectiveness of a DMP.
These findings could contribute to the on-going debate
in the Netherlands on whether the current bundled
payment system for single-disease DMPs are an inter-
mediate stage towards population-based financing [6].
Population based financing includes a risk-adjusted fixed
budget (either per group of patients or region) to cover
all health care provided by multiple professionals from
different disciplines. Savings compared to a pre-defined
benchmark are often shared between payer and provider.
A large variation in the cost-effectiveness of DMPs due to
the aforementioned factors, jeopardizes the successful
implementation of DMPs as means to achieve integration
of chronic care. Thus, a population-based financing with
larger scope in terms of covered population and provided
interventions, economies of scale that lower operatingcosts, and consensus of all stakeholders that ensures
successful implementation may appear attractive to Dutch
policy makers. However, the preconditions to introduce a
population-based financing are far from being reached [30]
and therefore, the implementation of DMPs on more
disease areas is still work in progress.
This study contributes to the growing body of inter-
national evidence on integrated care in several ways.
First, it highlights the necessity to adopt a broad set of
outcome measures and include the most important cost
items from different perspectives in the evaluation of
DMPs. Second, the findings of our study support the
previous studies that concluded that DMPs are positively
associated with improvements in patient lifestyle and
quality of care [20,31,32]. Third, our finding that DMPs
have the potential to become cost-effective in the long-
term, and the identification of factors that drive that
cost-effectiveness, could inform designers of integrated
care programs in other European countries. Fourth, the
limitation of disease-specific DMPs to address the needs
of complex patients could urge collective initiatives on a
European level to develop adequate models of integrated
care for this population.
Our study is one of very few studies providing insight
into health economic aspects of DMPs that includes
such a broad range of outcome measures and cost cat-
egories. However, we fully acknowledge the limitations
of the study design with respect to causality. At the start
of this study there were multiple initiatives to provide
integrated care across the entire country, stimulated by
the introduction of the bundled payment system and
other financial incentives. Therefore it was impossible to
create a control group at regional level. It was also difficult
to identify control groups within the same organization
because of the high risk of contamination [33]. This risk
is high because the implementation of a DMP requires
changes at an organisational level. For example, redesigning
the care-delivery process or training nurses in motivational
interviewing affects the entire organisation and the entire
target population. Therefore, we did not aim to compare
the DMPs to usual care but rather compare different DMPs
within a disease category. To optimize comparability, we
applied inverse probability weighting and corrected for
confounders in multivariate analysis. In addition, our results
may be object to regression to the mean bias. However, this
bias is probably limited because our sample size is relatively
large and the diseases included in our analysis are chronic
and progressive. These assumptions are supported by a
previous study that found minimal evidence of regression
to the mean in COPD-DMPs [34].
Conclusions
This study of the short-term effects of DMPs found
that the implementation of DMPs was associated with
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iour, such as physical activity and smoking, of patients
with CVR, diabetes and COPD. Since an increase in phys-
ical activity and an increase in self-efficacy were predictive
of an improvement in HR-QoL, DMPs that aim to
improve these are more likely to be effective. This study
has also shown the wide variation in development and
implementation costs between DMPs and pointed at the
importance of economies of scale. On this short term we
have not found statistically significant cost savings due to
DMPs, but it is likely that it takes more time before the
improvements in care lead to reductions in complications
and hospitalizations.
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